Analystreport

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at UBS Group AG from a "sell" rating to a "neutral" rating. They now have a $37.50 price target

Ionis Pharmaceuticals, Inc.  (IONS) 
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ionispharma.com